The invention is directed to compositions comprising a modified dextran and to uses thereof for the treatment of wounds in a subject or for delivering a protein, an olignonucleotide, a pharmaceutical agent, or a mixture thereof to a subject. The modified dextran in the compositions can form hydrogels via crosslinking.

This disclosure provides a hydrocolloid having a super absorbent material chemically bonded either directly or indirectly to a peroxide. The peroxide is within the hydrocolloid and the peroxide is in an amount of 0.05% to 2% by weight within the hydrocolloid.

A dressing composition for use as a skin dressing comprises an elastomeric-adhesive composition, and a zeolite comprising releasably adsorbed nitric oxide. The zeolite may comprise a transition metal cation such as Co, Fe, Mn, Ni, Cu, Zn, Ag or a mixture thereof as an extra-framework metal cation, preferably Zn. The elastomeric adhesive composition may be a hydro-colloid-adhesive composition comprising, hydrocolloid and elastomer. The dressing composition releases nitric oxide, which may have beneficial effects, when used on wounds or moist skin, with a substantially constant release rate over a long period of time. A dressing including a layer of the dressing composition has a backing layer and may have a release liner removably attached to the skin-contacting surface of the dressing layer.

Disclosed herein is a non-flowable and deformable hemostatic compositions comprised of a xerogel crosslinked powdered polysaccharide dispersed within a substantially anhydrous blend of: glycerol, and polyethylene glycol (PEG), wherein the PEG and glycerol are present in a ratio ranging from higher than 1:1.3: to below 1:2.7 by weight, respectively, and wherein the powder content in the composition is above 50%, by weight. Methods of making the non-flowable compositions, and uses of the compositions in methods for treating a wound or a bleeding tissue, such as bone tissue, are further disclosed.

The present invention provides for nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (FAH), as hemostatic agents designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. These hydrogels can be applied topically to the wound either on the skin in a laparotomy or as non-invasive manner in surgical procedures. Its nanostructure technology generates an adhesive stable fibrin clot required for hemostasis. The attachment properties of the hydrogel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed shortly after application.

The present invention provides for nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (FAH), as hemostatic agents designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. These hydrogels can be applied topically to the wound either on the skin in a laparotomy or as non-invasive manner in surgical procedures. Its nanostructure technology generates an adhesive stable fibrin clot required for hemostasis. The attachment properties of the hydrogel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed shortly after application.

A three-dimensional network aqueous gel and a manufacturing method thereof are disclosed. A water-soluble polymer is first added into a solvent and uniformly mixed, followed by hydrolysis to form a sol, and vacuum is applied to convert the sol into a gel, followed by a polycondensation reaction to form a three-dimensional network aqueous gel. The three-dimensional network aqueous gel is formed of the water-soluble polymer that includes a group including sodium alginate and sodium carboxymethyl cellulose. The water-soluble polymer is interconnected to form a three-dimensional network structure. The three-dimensional network aqueous gel is of a gel-enclosed form, which uses the three-dimensional network structure formed of a high-molecule polymer to enclose medicine, so as to more effectively protect the active ingredient and provide an effect of controlled released to thereby extend therapeutic period and reduce side effects of irritating skin.

The present invention discloses a partially crosslinked hydrogels blended composition with enhanced viscosity and yield stress, which is formed by the polymerization of one or more colloid monomers through crosslinking. The polymerization is initiated by a photoinitiator under irradiation of the light of a specific wavelength, which promotes crosslinking of the one or more colloid monomers. The hydrogels blended composition can be further crosslinked with one or more other colloid monomers through repeated excitation of the photoinitiator. The hydrogels blended composition can be polymerized into a gel upon re-irradiation, and can also be used as a biomaterial for wound repair, three-dimensional cell culture, personal nursing care, health care, medical and pharmaceutical applications.

The present invention discloses a partially crosslinked hydrogels blended composition with enhanced viscosity and yield stress, which is formed by the polymerization of one or more colloid monomers through crosslinking. The polymerization is initiated by a photoinitiator under irradiation of the light of a specific wavelength, which promotes crosslinking of the one or more colloid monomers. The hydrogels blended composition can be further crosslinked with one or more other colloid monomers through repeated excitation of the photoinitiator. The hydrogels blended composition can be polymerized into a gel upon re-irradiation, and can also be used as a biomaterial for wound repair, three-dimensional cell culture, personal nursing care, health care, medical and pharmaceutical applications.

The present disclosure provides a coacervate composition containing a protein drug, gelatin A, sodium alginate and an acid and a wound-healing agent including the same. The coacervate composition according to the present disclosure can be useful as a wound-healing material delivery system for effectively delivering a protein drug, particularly epidermal growth factor, to a wound site in the wound-healing field.